ACTB and cancer: The frequency of somatic mutations for ACTB is modest (1.2%) when considered globally across cancers (Table 1), increases to 2.7% when considered in the frame of DLCBL mutations (Figure 3c, Table 3) and amounts to approximately 10% and 11% in the DLBCL studies ranked 2nd and 3rd in Figure 1.